|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we investigated the actions of the AM-RAMP2 and 3 systems in the tumor microenvironment and their impact on metastasis.
|
31754214 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CLR/RAMP1, or CGRP receptor, antagonists have been developed for the treatment of migraine headache and osteoarthritis pain; whereas CLR/RAMP2, or ADM receptor, antagonists are being developed for the treatment of tumor growth/metastasis.
|
31150417 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Emerging data are however challenging this view, indicating that the cross-presenting machinery in DCs is suboptimally activated by direct PAMP recognition, and that endogenous inflammatory factors are the main drivers of DC-mediated cross-presentation within the tumor.
|
29904904 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mice that received the AM negative modulator, 16311, had worse colitis symptoms than their control counterparts, whereas mice injected with the AM positive modulator, 145425, had a lower number of tumors than their controls.
|
29235493 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Adrenomedullin (ADM) is a multi-functional peptide related to many kinds of tumors.
|
28091613 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Adrenomedullin has been shown to be overexpressed in many tumors, including gastric cancer tumors; however, its mechanism of action remains unclear.
|
29179449 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Adrenomedullin (AM) is a multifunctional peptide that is highly expressed in several tumors and plays an important role in angiogenesis and tumor growth after binding to its receptors, calcitonin receptor-like receptor/receptor activity-modifying protein 2 (CLR/RAMP2) and calcitonin receptor-like receptor/receptor activity-modifying protein 3 (CLR/RAMP3).
|
26762744 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, blocking adrenomedullin inhibited sunitinib-resistant tumor growth.
|
27556517 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ADM knockdown in tumor-bearing mice or administration of AMA, an ADM antagonist, significantly inhibited the recruitment of myelomonocytic cells and tumor angiogenesis.
|
27391260 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, the combination treatment of intratumoral MDR1 siRNA and DOX (Group 3) showed no significant anti-tumor efficacy in the untransfected Bel-7402/ADM (p>0.05) tumor model, suggesting poor in vivo transfection efficiency of MDR1 siRNA.
|
27272776 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A small-molecule AM antagonist was tested for its effects on AM-stimulated ex vivo bone cell cultures and co-cultures with tumor cells, where responses of tumor and bone were distinguished by species-specific real-time PCR.
|
25439669 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, combined treatment with cisplatin and ADM‑shRNA significantly decreased tumor growth in vivo compared with treatment with cisplatin or ADM‑shRNA alone.
|
24927229 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In human tissues ADM expression is upregulated in cancer type-specific manner, implicating potential role for adrenomedullin signaling in particular in RCC, where CLR localization suggests autocrine/paracrine mode for adrenomedullin action within the tumor microenvironment.
|
23969937 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, the combination of cisplatin and ADM-shRNA significantly reduces the tumor growth in vivo compared to treatment with cisplatin (p = 0.0046) or ADM-shRNA alone (p < 0.0001).
|
23715749 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Interestingly, we observed decreased expression of several breast cancer tumour suppressor genes (e.g., TAGLN, EGR1, BCL11b, CAV1) in response to both SRC-2 knockdown and PKA activation, whereas the expression of a number of other genes implicated in cancer progression (e.g., RET, BCAS1, TFF3, CXCR4, ADM) was increased.
|
23936147 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings highlight the potential importance of AM and its receptors in the progression of CRC and support the conclusion that αAM treatment inhibits tumor growth by suppression of angiogenesis and tumor growth, suggesting that AM may be a useful therapeutic target.
|
23634287 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These data show that tumor-secreted AM is a critical factor for driving both tumor and lymph node lymphangiogenesis.
|
23099649 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, arenobufagin inhibited the growth of HepG2/ADM xenograft tumors, which were associated with poly (ADP-ribose) polymerase cleavage, light chain 3-II activation and mTOR inhibition.
|
23393227 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Adrenomedullin (AM), a potent vasodilator peptide, is present in various types of tumors.
|
22294191 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We found that patients with high AM expression showed a higher incidence of metastasis, larger residual size of tumors after cytoreduction and shorter disease-free and overall survival time.
|
22400488 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In a novel preclinical model of CS-induced tumor progression, host exposure to CS extracts significantly elevated tumor ADM although systemic treatment with the ADM antagonist NSC16311 efficiently blocked tobacco-induced tumor growth.
|
22993405 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Adrenomedullin, which has altered cellular characteristics in tumour compared to healthy tissue, offers an understudied target with potential to modify endometrial cancer behaviour, complementing other treatments.
|
22178239 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These observations strongly support the concept that tumour angiogenesis is regulated by paracrine mechanisms and identify beside VEGF, AM as a potential tumour angiogenesis factor in vivo which constitutes a potential interesting molecular target in GBM treatment.
|
21458987 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Adrenomedullin (AM), a potent vasodilator peptide, present in various kinds of tumors.
|
19616043 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Adrenomedullin (AM), a multifunctional peptide, is highly expressed in several tumors and plays an important role in angiogenesis and tumor growth through its receptors: calcitonin receptor-like receptor/receptor activity-modifying protein 2 and 3 (CLR/RAMP2 and CLR/RAMP3).
|
19610056 |
2009 |